Samer Al Said

Freiburg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation.

Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation.

Journal: JACC. Advances

Published: March 16, 2026

Outcomes With Warfarin in Atrial Fibrillation: Individual Patient Data Analysis From Four Randomized Trials.

Outcomes With Warfarin in Atrial Fibrillation: Individual Patient Data Analysis From Four Randomized Trials.

Journal: JACC. Advances

Published: March 12, 2026

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.

Journal: JAMA cardiology

Published: February 04, 2026

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

Journal: Circulation

Published: January 30, 2026

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.

Journal: Circulation

Published: January 30, 2026

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.

Journal: Circulation

Published: June 23, 2025

Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis.

Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: February 24, 2025

A polygenic risk score for peripheral artery disease and major adverse limb events.

A polygenic risk score for peripheral artery disease and major adverse limb events.

Journal: European heart journal

Published: November 14, 2024

Long-Term Lipid Lowering With Evolocumab in Older Individuals.

Long-Term Lipid Lowering With Evolocumab in Older Individuals.

Journal: Journal of the American College of Cardiology

Published: August 25, 2024

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: January 24, 2024

Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease.

Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease.

Journal: Hamostaseologie

Published: October 18, 2021

Cochrane corner: NOACs in atrial fibrillation patients post-percutaneous coronary intervention.

Cochrane corner: NOACs in atrial fibrillation patients post-percutaneous coronary intervention.

Journal: Heart (British Cardiac Society)

Published: May 31, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026